Matthew Weston
Stock Analyst at UBS
(2.55)
# 2,207
Out of 5,124 analysts
5
Total ratings
100%
Success rate
16.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Weston
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DBX Dropbox | Assumes: Sell | $29 → $27 | $27.80 | -2.88% | 1 | Sep 18, 2025 | |
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $50.88 | - | 1 | Aug 5, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | n/a | $137.87 | - | 1 | Feb 13, 2025 | |
| AZN AstraZeneca | Upgrades: Buy | n/a | $91.93 | - | 2 | Feb 13, 2025 |
Dropbox
Sep 18, 2025
Assumes: Sell
Price Target: $29 → $27
Current: $27.80
Upside: -2.88%
Novo Nordisk
Aug 5, 2025
Downgrades: Neutral
Price Target: n/a
Current: $50.88
Upside: -
Novartis AG
Feb 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $137.87
Upside: -
AstraZeneca
Feb 13, 2025
Upgrades: Buy
Price Target: n/a
Current: $91.93
Upside: -